Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·Why did antibodies against an immune-cell brake fare differently in mice and people?
Review or Meta-AnalysisTracked over timeIn mice, anti-TIGIT antibodies that recruited other immune cells often controlled tumors better. In people, treatment alone disappointed and combinations gave mixed results.
-
Evidence date ·What the TIGIT immune brake reveals in myeloma and other blood cancers
Review or Meta-AnalysisTracked over timeMyeloma studies found that blocking TIGIT improved immune-cell activity in lab tests, while only some bone-marrow samples responded.
-
Evidence date ·What does CD155 do to tumor cells and immune cells, and where might TIGIT blockade fit?
Review or Meta-AnalysisTracked over timeA 2021 review reports that CD155 can promote cancer-cell growth. Its interaction with TIGIT can also inhibit immune cells, a reason to test TIGIT blockade.
-
Evidence date ·How tumor blood-vessel signals may shape immune defenses
Review or Meta-AnalysisA January 2021 review links tumor blood-vessel signaling to immune suppression and reports sharply different response rates across early combination trials.
-
Evidence date ·How can eye care protect sight when cancer spreads to the eye?
Review or Meta-AnalysisWhen cancer spreads to the eye, it most often affects the choroid. A review links longer survival to timely eye care and oncology referral.
-
Evidence date ·Why block two immune brakes together in cancer?
Review or Meta-AnalysisTracked over timeTwo immune checkpoints restrain T cells at different stages. A 2025 mini review explains why one antibody might target both in cancer research.
-
Evidence date ·How MEDI5752 directs CTLA-4 blockade toward activated T cells with PD-1
Peer-Reviewed PaperTracked over timeMEDI5752 favored CTLA-4 blockade on PD-1-positive T cells and showed stronger activity in vivo than separate antibodies used together.
-
Evidence date ·What patients reported about life after engineered immune-cell treatment
Review or Meta-AnalysisIn one study of adults at least a year after immune-cell therapy, physical health scores resembled general-population scores, but mental health scores were lower.
-
Evidence date ·When brain metastases need radiation during ongoing cancer treatment
Review or Meta-AnalysisA 2021 review found no skin toxicity and no clear rise in bleeding or clinically significant radiation necrosis across 77 studies; safety may vary by drug.
-
Evidence date ·Why treating a few tumors may not control cancer elsewhere
Review or Meta-AnalysisA 2021 review asks whether immunotherapy could help control cancer beyond the few tumors treated with focused radiation.